Record Earnings and AI Investments Could Be a Game Changer For Raymond James Financial (RJF)

• Raymond James Financial recently announced record quarterly and annual earnings, reporting full-year revenues of US$15.91 billion and net income of US$2.14 billion as of September 30, 2025, while also highlighting a record high in client assets and a growing adviser base.
• In addition to these financial milestones, the company invested more than US$1 billion in technology, including artificial intelligence initiatives, to enhance adviser capabilities and client service efficiency.
• We'll explore how these record results and sizable technology investments reshape Raymond James Financial's investment narrative and future growth outlook.

Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 36 best rare earth metal stocks of the very few that mine this essential strategic resource.

Raymond James Financial Investment Narrative Recap

To own shares of Raymond James Financial, an investor should have conviction in the firm's ability to keep growing client assets, attract top advisers, and translate technology investments into improved productivity and earnings. The record-setting earnings and adviser recruitment in recent quarters support this narrative, while increasing technology spend introduces some margin risk. The recent results reinforce the key near-term catalyst of adviser growth and high client asset inflows, while the most significant risk remains whether technology investments efficiently convert to stronger margins, so far, the impact of spending appears manageable.

Among recent announcements, the completion of a US$1.1 billion share repurchase program stands out. Consistent buybacks not only signal management’s confidence in the company’s cash position, but also support earnings per share growth, a point that bolsters the current growth catalyst of expanding client assets and adviser base through reinvestment and shareholder returns.

But it is worth noting that as technology spending rises, there remains a risk investors should be aware of if these investments don’t...

Read the full narrative on Raymond James Financial (it's free!)

Raymond James Financial's outlook anticipates $17.3 billion in revenue and $2.7 billion in earnings by 2028. This scenario is based on analysts' assumptions of 8.0% annual revenue growth and an earnings increase of $0.6 billion from the current $2.1 billion.

Uncover how Raymond James Financial's forecasts yield a $179.75 fair value, a 8% upside to its current price.

Exploring Other Perspectives

Six members of the Simply Wall St Community provided fair value estimates for Raymond James Financial, ranging from US$70.20 to US$189.67 per share. While some see significantly higher value, others are more cautious, reflecting ongoing debate around whether technology spending will translate to sustainable margin improvement.

Explore 6 other fair value estimates on Raymond James Financial - why the stock might be worth less than half the current price!

Build Your Own Raymond James Financial Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Raymond James Financial research is our analysis highlighting 4 key rewards that could impact your investment decision.
• Our free Raymond James Financial research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Raymond James Financial's overall financial health at a glance.

Interested In Other Possibilities?

Opportunities like this don't last. These are today's most promising picks. Check them out now:

• AI is about to change healthcare. These 33 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• The end of cancer? These 28 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com